特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
465222

鼻ポリープ:パイプライン製品の分析

Nasal Polyps (Nasal Polyposis) - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 90 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
鼻ポリープ:パイプライン製品の分析
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 90 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

鼻ポリープは、鼻あるいは鼻洞内の非癌性腫瘍です。症状は、鼻水、いびき、かゆみ、持続性の鼻詰まり、顔面痛、味覚喪失などです。危険因子として、喘息、嚢胞性線維症、チャーグ・ストラウス症候群(アレルギー性肉芽腫性血管炎)、アレルギー性真菌性副鼻腔炎などが挙げられます。治療は、アレルギーの治療のために副腎皮質ステロイドおよび抗ヒスタミン剤を、慢性/再発性感染症治療のために抗生物質を用います。

当レポートでは、鼻ポリープの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

鼻ポリープ;概要

治療薬の開発

  • パイプライン製品;概要
  • 企業別の製品
  • 企業で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Allakos Inc
  • Cumberland Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • OptiNose US Inc
  • Regeneron Pharmaceuticals Inc

薬剤プロファイル

  • AK-001
  • dupilumab
  • fluticasone propionate
  • ifetroban sodium
  • omalizumab

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Pipeline by AnaptysBio Inc, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Pipeline by GlaxoSmithKline Plc, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Pipeline by Idorsia Pharmaceutical Ltd, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Pipeline by Kyowa Kirin Co Ltd, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Pipeline by Novartis AG, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Pipeline by OptiNose Inc, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Pipeline by Pfizer Inc, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Dormant Projects, H2 2020
  • Nasal Polyps (Nasal Polyposis) - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12428IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps (Nasal Polyposis) - Pipeline Review, H2 2020, provides an overview of the Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline landscape.

Nasal polyps (Nasal polyposis) is an inflammatory condition develops in the nasal lining of nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-strauss syndrome and allergic fungal sinusitis. Treatment includes steroid medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasal Polyps (Nasal Polyposis) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3, 1 and 1 respectively.

Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Nasal Polyps (Nasal Polyposis) - Overview
  • Nasal Polyps (Nasal Polyposis) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Nasal Polyps (Nasal Polyposis) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Nasal Polyps (Nasal Polyposis) - Companies Involved in Therapeutics Development
  • AnaptysBio Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Idorsia Pharmaceutical Ltd
  • Kyowa Kirin Co Ltd
  • Novartis AG
  • OptiNose Inc
  • Pfizer Inc
  • Suzhou Connect Biopharmaceuticals Ltd
  • Nasal Polyps (Nasal Polyposis) - Drug Profiles
  • ACT-774312 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • benralizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CBP-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • etokimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fevipiprant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fluticasone propionate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nasal Polyps (Nasal Polyposis) - Dormant Projects
  • Nasal Polyps (Nasal Polyposis) - Discontinued Products
  • Nasal Polyps (Nasal Polyposis) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.